Annexon, Inc. (NASDAQ:ANNX) Position Increased by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC boosted its position in Annexon, Inc. (NASDAQ:ANNX - Free Report) by 56.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 1,029,680 shares of the company's stock after purchasing an additional 370,426 shares during the quarter. Mutual of America Capital Management LLC owned about 0.97% of Annexon worth $5,282,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. Parkman Healthcare Partners LLC lifted its position in Annexon by 0.5% during the third quarter. Parkman Healthcare Partners LLC now owns 328,613 shares of the company's stock valued at $1,945,000 after buying an additional 1,768 shares in the last quarter. The Manufacturers Life Insurance Company lifted its position in Annexon by 1.6% during the 3rd quarter. The Manufacturers Life Insurance Company now owns 159,586 shares of the company's stock worth $945,000 after acquiring an additional 2,450 shares in the last quarter. GSA Capital Partners LLP boosted its holdings in Annexon by 10.7% in the 3rd quarter. GSA Capital Partners LLP now owns 34,581 shares of the company's stock worth $205,000 after acquiring an additional 3,355 shares during the period. MetLife Investment Management LLC grew its position in Annexon by 11.8% in the third quarter. MetLife Investment Management LLC now owns 55,212 shares of the company's stock valued at $327,000 after acquiring an additional 5,814 shares in the last quarter. Finally, Rhumbline Advisers raised its stake in shares of Annexon by 4.3% during the fourth quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock valued at $728,000 after purchasing an additional 5,854 shares during the period.

Remove Ads

Annexon Stock Up 3.0 %

Shares of ANNX traded up $0.08 during midday trading on Friday, hitting $2.76. The company had a trading volume of 719,370 shares, compared to its average volume of 1,810,568. The stock has a market cap of $294.20 million, a price-to-earnings ratio of -2.63 and a beta of 1.14. The company's 50 day moving average price is $3.80 and its 200 day moving average price is $5.36. Annexon, Inc. has a 52 week low of $2.30 and a 52 week high of $8.40.

Annexon (NASDAQ:ANNX - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Equities analysts anticipate that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ANNX has been the topic of several analyst reports. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Annexon in a research note on Friday, November 15th. HC Wainwright restated a "buy" rating and set a $30.00 target price on shares of Annexon in a research note on Tuesday, December 17th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price target on shares of Annexon in a research note on Tuesday. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $15.80.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.